Insmed (INSM) said Thursday that the US Food and Drug Administration accepted its new drug application for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition.
The US regulator granted priority review to the new drug application and has set a target action date of Aug. 12, according to the company.
The application is based on data from the phase 3 Aspen study that showed brensocatib, at both doses tested, significantly reduced lung flare-ups and lowered lung function decline compared to a placebo over one year, Ismed added.
The company said it plans to file regulatory submissions for brensocatib in the European Union, UK and Japan in 2025.
Price: 81.00, Change: -0.44, Percent Change: -0.55
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。